Phio Pharmaceuticals Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

false 0001533040 0001533040 2025-11-03 2025-11-03

 

 

 

 

 

 

 

 

 

Registrant’s telephone number, including area code: (610) 947-0251

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

On November 3, 2025, Phio Pharmaceuticals Corp. ("Phio”) issued a press release announcing (i) 100% tumor clearance (Complete Response) in one patient, greater than 90% (Near Complete Response) in second patient and greater than 50% (Partial Response) in third patient at Day 36 with cutaneous squamous cell carcinoma and (ii) that the Safety Monitoring Committee has issued a favorable review of safety data at the maximum dose of INTASYL PH-762. These patients completed treatment in the fifth and final dose cohort of Phio’s ongoing Phase 1b dose escalation clinical trial (NCT 06014086).

 

The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

 

(d) Exhibits

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.